Categories: Pharmaceutical litigation

The Xarelto (rivaroxaban) litigation involves numerous lawsuits from across the country alleging that individuals taking Xarelto suffered severe or fatal bleeding or other injuries. They further allege that Bayer and related companies did not adequately warn prescribing physicians or consumers of the risks associated with Xarelto, including the potential for severe or fatal bleeding and the unavailability of a reversal agent to counteract Xarelto’s anticoagulation effects.

Pursuant to the 12/14/14 order from the Judicial Panel on Multidistrict Litigation, certain cases were transferred and consolidated in multidistrict litigation (an “MDL”) in the Eastern District of Louisiana and assigned to the Honorable Eldon E. Fallon for coordinated or consolidated pretrial proceedings with the actions already pending there. The MDL is referred to as: MDL No. 2592, In re: Xarelto (Rivaroxaban) Products Liability Litigation. The Court’s website for the Xarelto MDL is available by clicking here, and provides information about the litigation including current developments, pretrial orders, orders, minute entries, a calendar, and transcripts. Case developments are updated regularly on the Court’s website. Numerous lawsuits continue to be filed.

For more information about the Xarelto litigation, feel free to contact Pharmaceutical Attorney Pamela A. Borgess of BORGESS LAW, LLC at (567) 455-5955 or toll-free at (844) LAW-9144. You can also contact Borgess Law, LLC by submitting an online inquiry.  Borgess Law never charges a fee for an initial consultation.